← Leaderboards
Viviana A Simon
Icahn School Of Medicine At Mount Sinai
$21,556,427
Attributed
$23,858,119
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,217,841 · 20
By mechanism
R01$14,790,806 · 6
P01$11,338,633 · 3
U19$10,915,775 · 2
R21$2,808,952 · 6
R56$1,102,909 · 2
T32$260,766 · 1
Top collaborators
- Ana Fernandez-Sesma6 shared
- Tao Pan5 shared
- Ali Hassan Ellebedy3 shared
- Harm Van Bakel3 shared
- Dusan Bogunovic2 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Ana Fernandez-Sesma$24,867,465
- Benjamin Goldman-Israelow$1,110,912
- Florian Krammer$130,401,178
- Allen Zheng$179,804
- Michael Schotsaert$3,271,645
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionViralCellsImmuneVirusPhenotypeVariantImmune ResponseSamplingMapsResponseProteinsT-LymphocyteAntiviral AgentsPreventInsightGenomicsIn VivoResearch PersonnelVaccinationMolecularPathogenesisProgramsStructure
Grant awards (66)
Programming Long-lasting Immunity to Coronaviruses (PLUTO)$2,494,973
P01 · FY2025 · AI · contact PI
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)$2,265,730
U19 · FY2025 · AI
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains$1,001,583
P01 · FY2025 · AI · contact PI
Dissecting the drivers of persistent SARS-CoV-2 infections$844,997
R01 · FY2025 · AI · contact PI
Determinants of HIV latency in CD4+ T lymphocytes$818,975
R01 · FY2025 · AI · contact PI
Administrative Core$253,500
P01 · FY2025 · AI · contact PI
Clinical Core$219,992
U19 · FY2025 · AI · contact PI
Programming Long-lasting Immunity to Coronaviruses (PLUTO)$2,494,973
P01 · FY2024 · AI · contact PI
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)$2,265,730
U19 · FY2024 · AI
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains$1,037,822
P01 · FY2024 · AI · contact PI
Dissecting the drivers of persistent SARS-CoV-2 infections$844,998
R01 · FY2024 · AI · contact PI
Determinants of HIV latency in CD4+ T lymphocytes$844,304
R01 · FY2024 · AI · contact PI
Phenotyping of human immune responses to dengue vaccination and infection in Argentina$400,000
U19 · FY2024 · AI
US-Cuba Administrative Supplement to the Viral Immunity and Vaccination (VIVA) Human Immunology Project Consortium$399,999
U19 · FY2024 · AI
Clinical Core$272,530
U19 · FY2024 · AI · contact PI
Administrative Core$253,500
P01 · FY2024 · AI · contact PI
Programming Long-lasting Immunity to Coronaviruses (PLUTO)$2,506,857
P01 · FY2023 · AI · contact PI
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)$2,265,730
U19 · FY2023 · AI
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains$1,041,898
P01 · FY2023 · AI · contact PI
Dissecting the drivers of persistent SARS-CoV-2 infections$831,341
R01 · FY2023 · AI · contact PI
Clinical Core$277,117
U19 · FY2023 · AI · contact PI
Administrative Core$253,527
P01 · FY2023 · AI · contact PI
HIV latency driven microgliosis$211,250
R21 · FY2023 · MH · contact PI
Nasal RNA response to respiratory viral infections$207,875
R21 · FY2023 · AI
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)$2,265,730
U19 · FY2022 · AI
Clinical Core$283,217
U19 · FY2022 · AI · contact PI
Nasal RNA response to respiratory viral infections$264,875
R21 · FY2022 · AI
HIV latency driven microgliosis$253,500
R21 · FY2022 · MH · contact PI
Preventing CD4+ T memory cells from becoming HIV reservoirs$593,250
R01 · FY2021 · AI · contact PI
Preventing CD4+ T memory cells from becoming HIV reservoirs$593,250
R01 · FY2020 · AI · contact PI
HIV restriction by APOBEC3A$466,130
R01 · FY2020 · AI · contact PI
Defining the role of pseudouridine modifications in HIV biology$679,159
R56 · FY2019 · AI · contact PI
Preventing CD4+ T memory cells from becoming HIV reservoirs$593,250
R01 · FY2019 · AI · contact PI
HIV restriction by APOBEC3A$466,130
R01 · FY2019 · AI · contact PI
Preventing CD4+ T memory cells from becoming HIV reservoirs$593,250
R01 · FY2018 · AI · contact PI
HIV restriction by APOBEC3A$466,130
R01 · FY2018 · AI · contact PI
Interplay between Negative Regulators of Type I Interferon and HIV control$211,875
R21 · FY2018 · AI
HIV restriction by APOBEC3A$466,130
R01 · FY2017 · AI · contact PI
Interplay between Negative Regulators of Type I Interferon and HIV control$254,250
R21 · FY2017 · AI
N6-methyladenosine and the biology of HIV$202,132
R21 · FY2017 · AI · contact PI
HIV restriction by APOBEC3A$485,931
R01 · FY2016 · AI · contact PI
Targeting HIV persistence in CD4+ T memory stem cells$423,750
R56 · FY2016 · AI · contact PI
N6-methyladenosine and the biology of HIV$261,882
R21 · FY2016 · AI · contact PI
HIV Evolution Driven by Intracellular Defenses$470,610
R01 · FY2015 · AI · contact PI
HIV Evolution Driven by Intracellular Defenses$619,293
R01 · FY2014 · AI · contact PI
Genomic Determinants of Intrinsic Antiviral Host Defenses$426,123
R01 · FY2014 · AI · contact PI
HTLV-1 antagonists of HIV restriction factors$210,069
R21 · FY2014 · AI · contact PI
HIV Evolution Driven by Intracellular Defenses$75,224
R01 · FY2014 · AI · contact PI
Genomic Determinants of Intrinsic Antiviral Host Defenses$400,652
R01 · FY2013 · AI · contact PI
HIV Evolution Driven by Intracellular Defenses$370,216
R01 · FY2013 · AI · contact PI
HTLV-1 antagonists of HIV restriction factors$252,444
R21 · FY2013 · AI · contact PI
Genomic Determinants of Intrinsic Antiviral Host Defenses$426,245
R01 · FY2012 · AI · contact PI
HIV Evolution Driven by Intracellular Defenses$412,222
R01 · FY2012 · AI · contact PI
Genomic Determinants of Intrinsic Antiviral Host Defenses$426,148
R01 · FY2011 · AI · contact PI
Genomic Determinants of Intrinsic Antiviral Host Defenses$447,503
R01 · FY2010 · AI · contact PI
Physician Scientist Research Training in Pathogenesis of Viral Diseases$131,516
T32 · FY2010 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$354,743
R01 · FY2009 · AI · contact PI
Physician Scientist Research Training in Pathogenesis of Viral Diseases$129,250
T32 · FY2009 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$16,950
R01 · FY2009 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$354,743
R01 · FY2008 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$361,613
R01 · FY2007 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$319,796
R01 · FY2006 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$55,878
R01 · FY2006 · AI · contact PI
HIV-1 evolution driven by intracellular defenses$344,781
R01 · FY2005 · AI
Mechanisms of multi-drug resistant HIV-1 adaptation$239,400
R21 · FY2003 · AI
Mechanisms of multi-drug resistant HIV-1 adaptation$239,400
R21 · FY2002 · AI